The DOI matches its Crossref record; 268 of the 270 references it cites were found in a registry or an index.
Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes
Open accessAbstract
An increasing amount of research aims at recognizing the molecular mechanisms involved in long-lasting brain architectural changes induced by antipsychotic treatments. Although both structural and functional modifications have been identified following acute antipsychotic administration in humans, currently there is scarce knowledge on the enduring consequences of these acute changes. New insights in immediate-early genes (IEGs) modulation following acute or chronic antipsychotic administration may help to fill the gap between primary molecular response and putative long-term changes. Moreover, a critical appraisal of the spatial and temporal patterns of IEGs expression may shed light on the functional "signature" of antipsychotics, such as the propensity to induce motor side effects, the potential neurobiological mechanisms underlying the differences between antipsychotics beyond D2 dopamine receptor affinity, as well as the relevant effects of brain region-specificity in their mechanisms of action. The interest for brain IEGs modulation after antipsychotic treatments has been revitalized by breakthrough findings such as the role of early genes in schizophrenia pathophysiology, the involvement of IEGs in epigenetic mechanisms relevant for cognition, and in neuronal mapping by means of IEGs expression profiling. Here we critically review the evidence on the differential modulation of IEGs by antipsychotics, highlighting the association between IEGs expression and neuroplasticity changes in brain regions impacted by antipsychotics, trying to elucidate the molecular mechanisms underpinning the effects of this class of drugs on psychotic, cognitive and behavioral symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–268 of 268
de Bartolomeis, A., Marmo, F., Buonaguro, E. F., Rossi, R., Tomasetti, C., & Iasevoli, F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.014 · Cited by 38
Self-citationAmbesi‐Impiombato, A., Panariello, F., Dell’Aversano, C., Tomasetti, C., Muscettola, G., & de Bartolomeis, A. (2007) · Synapse · doi:10.1002/syn.20385 · Cited by 38
Self-citationKim, H., Cheon, Y., Modi, H. R., Rapoport, S. I., & Rao, J. S. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2671-7 · Cited by 38
BDNF polymorphisms are associated with schizophrenia onset and positive symptoms
Zhang, X. Y., Chen, D., Tan, Y., Tan, S., Luο, X., Zuo, L., & Soares, J. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.009 · Cited by 38
Snyder, J. S., Clifford, M. A., Jeurling, S. I., & Cameron, H. A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.06.025 · Cited by 37
Robbins, M., Critchlow, H., Lloyd, A., Cilia, J., Clarke, J. D. W., Bond, B. C., Jones, D., & Maycox, P. R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107081521 · Cited by 37
Amin, E., Pearce, J. M., Brown, M. W., & Aggleton, J. P. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05131.x · Cited by 36
Yamada, H., Kuroki, T., Nakahara, T., Hashimoto, K., Tsutsumi, T., Hirano, M., & Maeda, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.11.011 · Cited by 36
Eells, J. B., Wilcots, J., Sisk, S., & Guo‐Ross, S. X. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9642-z · Cited by 36
Penke, Z., Chagneau, C., & Laroche, S. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00048 · Cited by 35
Inverse Regulation of Plasticity-related Immediate Early Genes by Calcineurin in Hippocampal Neurons
Lam, B., Zhang, W., Enticknap, N., Haggis, E., Cader, M. Z., & Chawla, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901121200 · Cited by 35
Li, Y., Ge, S., Li, N., Chen, L., Zhang, S., Wang, J., Wu, H., Wang, X., & Wang, X. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.063 · Cited by 35
Homer1a protein expression in schizophrenia, bipolar disorder, and major depression
Leber, S. L., Llenos, I. C., Miller, C. L., Dulay, J. R., Haybaeck, J., & Weis, S. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1776-x · Cited by 34
Bubser, M., & Deutch, A. Y. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01903.x · Cited by 33
Wang, H.-X., & Gao, W. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.024 · Cited by 33
de Bartolomeis, A., Iasevoli, F., Marmo, F., Buonaguro, E. F., Eramo, A., Rossi, R., Avvisati, L., Latte, G., & Tomasetti, C. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.003 · Cited by 32
Self-citationOzdemir, H., Ertuğrul, A., Başar, K., & Saka, E. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.05.009 · Cited by 31
Verma, V., Lim, E. P., Han, S. P., Nagarajah, R., & Dawe, G. S. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.09.002 · Cited by 31
Antipsychotic drugs modulate Arc expression in the rat brain
Fumagalli, F., Frasca, A., Racagni, G., & Riva, M. A. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.09.001 · Cited by 31
Molteni, R., Calabrese, F., Mancini, M., Racagni, G., & Riva, M. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1276-7 · Cited by 31
Dell’Aversano, C., Tomasetti, C., Iasevoli, F., & de Bartolomeis, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.01.006 · Cited by 30
Self-citationDragunow, M. (1990) · Brain Research · doi:10.1016/0006-8993(90)91357-m · Cited by 30
Semba, J., Sakai, M. W., Suhara, T., & Akanuma, N. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00009-1 · Cited by 30
Dahl, J. P., Kampman, K. M., Oslin, D. W., Weller, A. E., Lohoff, F. W., Ferraro, T. N., Brien, C. P. O., & Berrettini, W. H. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00010 · Cited by 29
Gill, K. M., Bernstein, I. L., & Mizumori, S. J. Y. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.12.011 · Cited by 29
Luoni, A., Fumagalli, F., Racagni, G., & Riva, M. A. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.008 · Cited by 28
Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain
Nakahara, T., Kuroki, T., Hashimoto, K., Hondo, H., Tsutsumi, T., Motomura, K., Ueki, H., Hirano, M., & Uchimura, H. (2000) · Neuroreport · doi:10.1097/00001756-200002280-00025 · Cited by 28
Transcriptional Mechanisms Underlying Addiction-Related Structural Plasticity
Maze, I. S., & Russo, S. J. (2010) · Molecular Interventions · doi:10.1124/mi.10.4.5 · Cited by 28
Kovács, K., Csejtei, M., & Laszlovszky, I. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00163-5 · Cited by 28
HOMER1 Promoter Analysis in Parkinson’s Disease: Association Study with Psychotic Symptoms
Luca, V. D., Annesi, G., Marco, E. V. D., de Bartolomeis, A., Nicoletti, G., Pugliese, P., Muscettola, G., Barone, P., & Quattrone, A. (2009) · Neuropsychobiology · doi:10.1159/000230689 · Cited by 27
Identification of Optogenetically Activated Striatal Medium Spiny Neurons by Npas4 Expression
Bepari, A. K., Sano, H., Tamamaki, N., Nambu, A., Tanaka, K. F., & Takebayashi, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052783 · Cited by 27
Shepard, R. M., Heslin, K. A., & Coutellier, L. D. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.012 · Cited by 27
Srivas, S., & Thakur, M. K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0047-4 · Cited by 27
C Young, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00203-0 · Cited by 26
Sakuma, K., Komatsu, H., Maruyama, M., Imaichi, S., Habata, Y., & Mori, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118510 · Cited by 26
Signaling Pathways Relevant to Cognition-Enhancing Drug Targets
Ménard, C., Gaudreau, P., & Quirion, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_3 · Cited by 24
Buonaguro, E. F., Iasevoli, F., Marmo, F., Eramo, A., Latte, G., Avagliano, C., Tomasetti, C., & de Bartolomeis, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.02.012 · Cited by 24
Self-citationWiig, K. A., Whitlock, J. R., Epstein, M. H., Carpenter, R. L., & Bear, M. F. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.02.001 · Cited by 24
Gentzel, R. C., Toolan, D. M., Roberts, R., Koser, A. J., Kandebo, M., Hershey, J. C., Renger, J. J., Uslaner, J. M., & Smith, S. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.024 · Cited by 21
Kagaya, S., Hashida, R., Ohkura, N., Tsukada, T., Sugita, Y., Terakawa, M., Tsujimoto, G., Katsunuma, T., Akasawa, A., Matsumoto, K., et al. (2005) · International Archives of Allergy and Immunology · doi:10.1159/000085430 · Cited by 21
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21
Self-citationVerma, V., Rasmussen, K., & Dawe, G. S. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.010 · Cited by 21
Bourhis, E., Maheux, J., Rouillard, C., & Lévesque, D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05455.x · Cited by 20
Waller, J. A., Tamm, J. A., Abdourahman, A., Pehrson, A. L., Li, Y., Cajina, M., & Sánchez, C. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.014 · Cited by 20
Openshaw, R. L., Thomson, D. M., Penninger, J. M., Pratt, J. A., & MORRIS, B. J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4463-y · Cited by 20
Boutet-Robinet, E. A., Geurts, M., Maloteaux, J., & Pauwels, P. J. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01923-1 · Cited by 19
Emsley, R. A., Asmal, L., du Plessis, S., Chiliza, B., Kidd, M., Carr, J. A., & Vink, M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.09.014 · Cited by 18
Luoni, A., da Rocha, F. F., & Riva, M. A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.008 · Cited by 18
Moore, T. M., Brown, T., Cade, M., & Eells, J. B. (2008) · Synapse · doi:10.1002/syn.20550 · Cited by 18
A direct role for c-fos in AP-1-dependent gene transcription.
Herrera, R., Agarwal, S., Walton, K., Satterberg, B., Distel, R. J., Goodman, R. H., Spiegelman, B. M., & Roberts, T. M. (1990) · PubMed · Cited by 17
Gerlach, R., Beck, M., Zeitschel, U., & Seifert, V. (2002) · Neurological Research · doi:10.1179/016164102101200654 · Cited by 17
de Bartolomeis, A., Avvisati, L., Iasevoli, F., & Tomasetti, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.034 · Cited by 17
Self-citationNR4A2: Effects of an “Orphan” Receptor on Sustained Attention in a Schizophrenic Population
Ancín, I., Cabranes, J. A., Vázquez-Álvarez, B., Santos, J. L., Sánchez‐Morla, E. M., Alaerts, M., Del‐Favero, J., & Barabash, A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr176 · Cited by 17
Fernandes, A. R., & Chari, D. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.039 · Cited by 17
Changes in brain functional connectivity after chronic haloperidol in rats: a network analysis
Wheeler, A. L., Creed, M. C., Voineskos, A. N., & Nóbrega, J. N. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000042 · Cited by 15
de Bartolomeis, A., Marmo, F., Buonaguro, E. F., Latte, G., Tomasetti, C., & Iasevoli, F. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.015 · Cited by 15
Self-citationAssociation of the orphan nuclear receptor NR4A1 with tardive dyskinesia
Novak, G., Gallo, A., Zai, C. C. H., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Voineskos, A. N., Remington, G. J., Kennedy, J. L., Lévesque, D., et al. (2009) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283351221 · Cited by 14
Schizophrenia: What’s Arc Got to Do with It?
Managò, F., & Papaleo, F. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00181 · Cited by 14
Maheux, J., Vuillier, L., Mahfouz, M., Rouillard, C., & Lévesque, D. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000630 · Cited by 13
Hayashi, Y., Okamoto, K., Bosch, M., & Futai, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_15 · Cited by 13
Jones, K. L., & Barr, G. A. (2000) · Synapse · doi:10.1002/1098-2396(200102)39:2 · Cited by 11
Collins, C. M., Wood, M. D., & Elliott, J. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114536788 · Cited by 11
Schizophrenia-associated Risk and Protective Variants of c-Fos Encoding Gene
Boyajyan, A. S., Zakharyan, R., Atshemyan, S., Chavushyan, A., & Mkrtchyan, G. (2015) · Recent Advances in DNA & Gene Sequences (Formerly Recent Patents on DNA & Gene Sequences) · doi:10.2174/2352092209666150223113334 · Cited by 9
Tien, L., Ho, I.-K., & Ma, T. (2010) · NeuroToxicology · doi:10.1016/j.neuro.2010.02.002 · Cited by 7
Shirayama, Y., Hashimoto, K., Matsuki, H., Tsunashima, K., Iyo, M., Higuchi, T., & Minabe, Y. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01738-2 · Cited by 6
Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus
Schubert, K. O., Föcking, M., Wynne, K. J., & Cotter, D. (2015) · PROTEOMICS · doi:10.1002/pmic.201500242 · Cited by 6
Acute drug-induced spine changes in the nucleus accumbens are dependent on β-adducin
Engmann, O., Giralt, A., & Girault, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.035 · Cited by 6
Jonnal (2000) · doi:10.1002/1096-8628(20001204)96:6
Flagged first, then by citations
2 of the 270 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder
Gandal, M. J., Zhang, P., Hadjimichael, E., Walker, R. L., Chen, C., Liu, S., Won, H., van Bakel, H., Varghese, M., Wang, Y., et al. (2018) · Science · doi:10.1126/science.aat8127 · Cited by 1,247
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Yohn, S. E., Weiden, P. J., Felder, C. C., & Stahl, S. M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.006 · Cited by 113
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 96
Self-citationde Bartolomeis, A., Barone, A., Begni, V., & Riva, M. A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106078 · Cited by 79
Polese, D., Fornaro, M., Palermo, M., Luca, V. D., & de Bartolomeis, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00210 · Cited by 78
Metadata
- Authors
- de Bartolomeis, A., Buonaguro, E. F., Latte, G., Rossi, R., Marmo, F., Iasevoli, F., & Tomasetti, C.
- Affiliations
- Federico II University Hospital (IT)
- ORCID
- Venue
- Frontiers in Behavioral Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-12-11
- Volume
- 11
- Pages
- 240-240
- ISSN
- 1662-5153 (ISSN-L)
- PMC
- PMC5732183
- OpenAlex
- W2771406275
- Cited by
- 44
- References
- 270
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 9 · 2019: 4 · 2018: 3
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Behavioral Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- immediate early genes, antipsychotic drugs, neuroplasticity, schizophrenia, epigenetics, dopamine D2 receptor, motor side effects, brain region specificity, gene expression profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review